The Future of Scalp Cooling in Chemotherapy-Induced Alopecia

by

Chemotherapy-induced alopecia (CIA) is among the disturbing side effects experienced by cancer patients, and it is treated as one of the significant problems. Alopecia is a condition that affects the psychological well-being of a patient as it interferes with the appearance of hair, self-esteem, self-image, and the quality of life of the patient. However, due to improvements in technologies in the medical field, scalp cooling is used as a way of avoiding this side effect. Equipment like the DigniCap® has helped minimize hair loss during chemotherapy through the use of colds on the scalp, and vasoconstriction reduces the concentration of the chemotherapy drugs taken up by the hair follicles. This article aims to discuss the prospects of scalp cooling in the treatment of CIPN with a focus on the findings of recent works and clinical trials.

The Mechanism of Scalp Cooling

Scalp cooling in its mechanism constricts blood vessels beneath the skin to lower the temperature of the hair follicles. This process reduces the impact of the chemotherapy drug on the hair follicles, hence the reduction of hair loss. The therapy usually entails wearing a cap consisting of a coolant, specifically for the period before, during, and after chemotherapy. This cooling cap is to be worn for a certain duration as prescribed for the best therapy option to prevail. This technique has been increasingly practiced since it is not invasive and could enhance the quality of life of cancer patients.

Clinical Evidence Supporting Scalp Cooling

It is worth noting that several clinical trials have shown the effectiveness of devices such as scalp cooling systems in preventing CIA. One of the few prospective trials recruited early-stage breast cancer patients who had received neoadjuvant/adjuvant chemotherapy. The present research employed the DigniCap® system, which is a popular scalp cooling system, to evaluate a hair loss protective strategy. The efficacy criterion was based on the patient’s self-assessment of hair loss using the Dean scale reporting under fifty percent.

Patients of the study were 135, among them 74% of patients underwent adjuvant chemotherapy and 26% underwent neoadjuvant chemotherapy. The kinds of chemotherapy were different. Effectiveness was at 77% of the alopecia cases at three weeks of commencement of chemotherapy and 60% at three weeks of completion of the treatment. From these observations, higher efficacies appear to be achieved in non-antracycline chemotherapy groups, and thus scalping cooling would need to be applied across chemotherapy treatments.

Yearwise Publication Trend on “chemotherapy”

Find publication trends on relevant topics

Patient Tolerability and Compliance

The acceptability of patients when it comes to compliance with scalp cooling is one of the most important broad measures. In the mentioned study, scalp cooling has been acceptably tolerated, but still, 29 patients out of 135 (21.5%) patients have dropped out of the treatment. Most of the patients stopped treatment due to alopecia (16 patients), low tolerability of scalp cooling (8 patients), or both (5 patients).

From the results presented, it appears that most of the patients find scalp cooling helpful, but a part of the cohort is likely to report discomfort or lack of benefit from the intervention. The management of these obstacles is crucial in enhancing the patients’ compliance so that more patients will be able to avail of scalp cooling.

Technological Advancements and Future Directions

Scalp cooling is still far from its perfect usage for those who lost hair due to chemotherapy, and further improvements will be based on the advancements and technological changes. Today’s ongoing research is aimed at increasing the efficiency and comfort of scalp cooling devices and also making them more portable. Such adaptations include enhanced cap constructions, the introduction of new cooling fluids, and enhanced temperature regulation technologies being developed.

Moreover, more specific cooled scalp therapy regimens depending on the patient’s features and the administered chemotherapy drugs are being investigated. All these treatment methods tend to focus on a more individual treatment for the desired hair to protect the hair follicles more and at the same time reduce pain as much as possible.

Further, the simultaneous use of other comfort activities such as nutritional support and psychological counseling together with scalp cooling helps in addressing CIA comprehensively. This paper aims to argue that it is possible to go a long way towards helping patients through the changes enforced by chemotherapy by paying more attention to such physical and emotive realities as hair loss.

Recent Publications on “chemotherapy”

Find publications on relevant topics

Overcoming Barriers to Adoption

Nevertheless, escalatory use of scalp cooling in clinical practice is met with some challenges. Among the issues that may represent a problem is the cost of the scalp cooling devices and treatment. Some of the patients feel the additional cost to be a load in their accounts in the event the costs are not covered by an insurance ITA. Fighting for reimbursement for scalp cooling within the insurance plans is crucial for expanding the option’s availability to more individuals.

The other challenge once again is the lack of set policies and procedures for the practice of scalp cooling. Different treatments and implementation and no particular guidelines to follow influence the effectiveness and cohesiveness of the scalp cooling treatment. Conducting
research-based protocols and handling reachable teaching programs for the healthcare givers may assist in making scalp cooling treatment as effective and secure as possible intervention.

Patient Education and Awareness

Patient awareness of the advantages and disadvantages of scalp cooling should be raised to avoid the absence of the patient’s consent. Subsequently, patients should have adequate information about hair preservation possibilities, the process, and possible complications. Scalp cooling options should be discussed by healthcare providers, usually to calm the patient’s complaints or to give them an understanding of what to expect.

Conclusion

In other words, scalp cooling can be regarded as a major improvement in the approach to the treatment of ICAs. It has been proven clinically useful for hair loss, specifically in the cases of patients who undergo a non-anthracycline chemotherapy cycle. Altogether, there are certain limitations with the present scalp cooling method; patient tolerability, cost, and standardization are some of them; nonetheless, future research and development of new technologies have a possible solution for scalp cooling. Therefore, by ensuring that scalp cooling aids are comfortable and easily usable and/or included as part of patient support care plans, clinicians can improve the quality of life of people with cancer going through chemotherapy.

References

  1. Giarratano T, Frezzini S, Zanocco M, Giorgi CA, Mioranza E, Miglietta F, Griguolo G, Falci C, Faggioni G, Tasca G, Di Liso E, Vernaci G, Menichetti A, Mantiero M, Grosso D, Guarneri V, Dieci MV. Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study. Breast J. 2020 Jul;26(7):1296-1301. doi: 10.1111/tbj.13711. Epub 2019 Dec 14. PMID: 31837103.
  2. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. PMID: 31825192; PMCID: PMC7458671.
  3. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020 Feb 6;382(6):514-524. doi: 10.1056/NEJMoa1911149. Epub 2019 Dec 11. PMID: 31826360.
  4. Carlo MI, Ravichandran V, Srinavasan P, Bandlamudi C, Kemel Y, Ceyhan-Birsoy O, Mukherjee S, Mandelker D, Chaim J, Knezevic A, Rana S, Fnu Z, Breen K, Arnold AG, Khurram A, Tkachuk K, Cipolla CK, Regazzi A, Hakimi AA, Al-Ahmadie H, Dalbagni G, Cadoo KA, Walsh MF, Teo MY, Funt SA, Coleman JA, Bochner BH, Iyer G, Solit DB, Stadler ZK, Zhang L, Rosenberg JE, Taylor BS, Robson ME, Berger MF, Vijai J, Bajorin DF, Offit K. Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. J Clin Oncol. 2020 Feb 10;38(5):406-414. doi: 10.1200/JCO.19.01395. Epub 2019 Dec 3. PMID: 31794323; PMCID: PMC7351337.
  5. Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, Yamada Y, Watanabe D, Ishihara T, Suzuki A, Yoshida K. Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study. Oncologist. 2020 Mar;25(3):e469-e476. doi: 10.1634/theoncologist.2019-0541. Epub 2019 Nov 20. PMID: 32162797; PMCID: PMC7066722.
  6. Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O’Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, André T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020 Jan 1;38(1):11-19. doi: 10.1200/JCO.19.02107. Epub 2019 Nov 14. PMID: 31725351; PMCID: PMC7031958.
  7. Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019 Nov;30 Suppl 8:viii23-viii30. doi: 10.1093/annonc/mdz282. Epub 2019 Dec 24. PMID: 32223935.

Top Experts on “chemotherapy“